CORPORATE OVERVIEW
Parallax Clinical Research was founded by a group of experienced scientists and clinicians dedicated to the facilitation of translational research. Translational research is defined as: “The process of translating discoveries in the laboratory into clinical interventions for the diagnosis, treatment, prognosis, or prevention of disease with a direct benefit to human health.” Parallax has established a network of scientific, clinical and operational experts who are committed to leveraging their cumulative pharmaceutical knowledge to facilitate the development of novel therapeutics. Parallax has worked with over 20 pharmaceutical and biotechnology companies, facilitating their entry into clinical trials.
Beginning with the process of discovery,
through animal toxicology, pharmacology, and increasingly
complex phase 1, 2, and 3 studies designed to satisfy the most
demanding regulatory reviewers, the modern drug discovery
process is complex and requires the application of extensive
resources.
To successfully gather the essentials of a successful NDA
application requires the input of a wide range of skills and
expertise. At Parallax Clinical Research, we have put together
an outstanding group of skilled professionals with many years of
experience in the pharma industry to assist in the process. We
pride ourselves on our scientific and operational expertise that
would make us an asset to assist with all aspects of the
clinical development process from development strategy to
submission.
MANAGEMENT TEAM
Richard A. Kolchin earned his B.S. in Molecular Biophysics and Biochemistry at Yale and his M.D. and Ph.D. in Microbiology and Immunology at SUNY-Downstate. He completed an Internal Medicine residency at Kings County and Brooklyn V.A. Hospitals and an Allergy/Immunology fellowship at Brigham and Women’s Hospital. He is board certified both in Internal Medicine and in Allergy/Immunology. He has worked primarily as an academic hospitalist in Internal Medicine with a part-time private practice in Allergy/Immunology since 1987. He began working full-time for Parallax Clinical Research in August, 2009.
Stuart Apfel is a founder and President of Parallax Clinical Research, and co-founder of Parallax Online. He earned his BA in Biophysics at Columbia University and received his MD from the Albert Einstein College of Medicine. He completed his training in Neurology at Einstein and is board certified in Neurology and Psychiatry. He worked as a full time academic neurologist at Albert Einstein for 10 years, where his research focused on the clinical application of neurotrophic factors to disorders of the peripheral nervous system. He began working in the pharmaceutical industry in the year 2000, and together with Emelia Klonowski founded Parallax Clinical Research, LLC in 2005. He has extensive experience working on every phase of clinical drug development and has served as an advisor to many biotechnology and pharmaceutical companies as well as investment firms in the biotechnology sector.
Emelia Klonowski is a founder and Vice President of Parallax Clinical Research, and co-founder of Parallax Online. She has over 20 years’ experience in drug development and completed her BA in Biology at Lehman College and received an MPH in epidemiology at the Mailman School of Public Health at Columbia University. In addition, she completed an Epidemiology Fellowship Program at the New York Academy of Medicine. She began her career at the Albert Einstein College of Medicine Kennedy Center Neurophysiology Lab and then went on to direct the activities of the stroke team for the conduct of several sponsor-based and NIH trials at the Stern Stroke Center at Montefiore Medical Center. She also served as the resident epidemiologist. Her expertise in transcranial Doppler ultrasonography resulted in the creation of a neurology residency training program. She has held senior clinical scientist positions at Novartis and Purdue Pharma and has directed the activities of many global early and late-phase clinical trials. She has provided scientific and operational input into the clinical development strategy for several biotech and pharmaceutical companies from IND filing through NDA submission.